Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tavist Sinus, available in August, is first Novartis product launch.

This article was originally published in The Tan Sheet

Executive Summary

NOVARTIS TAVIST SINUS TO HIT SHELVES IN AUGUST as the first offspring of the December 1996 marriage of Ciba and Sandoz. Unlike older siblings Tavist-1 and Tavist-D, Tavist Sinus does not contain clemastine fumarate. Each Tavist Sinus tablet contains 500 mg acetaminophen and 30 mg pseudoephedrine HCl, a familiar monograph combination available in a number of currently marketed OTCs, including McNeil's Sine-Aid and Warner Wellcome's Sinutab.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel